Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ESC 2022 | REVIVED-BCIS2

The REVIVED-BCI2 included 700 patients with ejection fraction 35% with extended coronary artery disease and plausible PCI.

ESC 2022

Patients were randomized to PCI plus optimal and complete medical treatment (OMT) according to the current guidelines.

347 patients received PCI and 353 OMT.

Primary end point was all cause death and hospitalization for cardiac failure. 

There were no differences between the populations.

At 11-month follow-up, there were no differences in primary end point (PCI 37.2% vs OMT 38%). Neither were there differences in primary end point components or the presence of AMI. 

The need for unplanned revascularization and myocardial ischemia were more frequent in patients receiving OMT.

Ejection fraction at 2 years was 27% at 6 and 12 months with no difference between the strategies. 

Read also: ESC 2022 | PERSPECTIVE: Efficacy and Safety of Sacubitril/Valsartan Compared with Valsartan in Cognitive Function of Patients with Cardiac Failure and Preserved Function.

Quality of life, according to the Kansas City Cardiomyopathy Questionnaire (KCCQ), was superior in patients receiving PCI at 6 months but with no difference at 2 years. 

We can conclude that this study on patients with severe ventricular dysfunction undergoing OMT at maximal tolerable doses, revascularization with PCI did not result in lower incidence of all cause death or hospitalization for cardiac failure. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...